Knowns and unknowns of bone metastases in patients with neuroendocrine neoplasms: A systematic review and meta-analysis
Authors
Garcia-Torralba, EsmeraldaSpada, F.
Lim, Kok Haw Jonathan
Jacobs, Timothy
Barriuso, Jorge
Mansoor, Was
McNamara, Mairead G
Hubner, Richard A
Manoharan, Prakash
Fazio, Nicola
Valle, Juan W
Lamarca, Angela
Affiliation
Department of Medical Oncology, ENETS Centre of Excellence, The Christie NHS Foundation Trust, ManchesterIssue Date
2021
Metadata
Show full item recordAbstract
Objective: This systematic review and meta-analysis aimed to develop an evidence-based summary of current knowledge of bone metastases (BMs) in neuroendocrine neoplasms (NENs), inform diagnosis and treatment and standardise management between institutions. Methods: PubMed, Medline, EMBASE and meeting proceedings were searched for eligible studies reporting data on patients with BMs and NENs of any grade of differentiation and site; poorly-differentiated large/small cell lung cancer were excluded. Data were extracted and analysed using STATA v.12. Meta-analysis of proportions for calculation of estimated pooled prevalence of BM and calculation of weighted pooled frequency and weighted pooled mean for other variables of interest was performed . Results: A total of 149 studies met the eligibility criteria. Pooled prevalence of BMs was 18.4% (95% CI 15.4-21.5). BMs were mainly metachronous with initial diagnosis of NEN (61.2%) and predominantly osteoblastic; around 61% were multifocal, with a predisposition in axial skeleton. PET/CT seemed to provide (together with MRI) the highest sensitivity and specificity for BM detection. Almost half of patients (46.4%) reported BM-related symptoms: pain (66%) and skeletal-related events (SREs, fracture/spinal cord compression) (26.2%; weightedweighted mean time-to-SRE 9.9 months). Management of BMs was multimodal [bisphosphonates and bone-modifying agents (45.2%), external beam radiotherapy (34.9%), surgery (14.8%)] and supported by little evidence. Overall survival (OS) from the time of diagnosis of BMs was long [weighted mean 50.9 months (95% CI 40.0-61.9)]. Patients with BMs had shorter OS [48.8 months (95% CI 37.9-59.6)] compared to patients without BMs [87.4 months (95% CI 74.9-100.0); p = 0.001]. Poor performance status and BM-related symptoms were also associated with worse OS. Conclusions: BMs in patients with NENs remain underdiagnosed and undertreated. Recommendations for management of BMs derived from current knowledge are provided. Prospective studies to inform management are required.Citation
Garcia-Torralba E, Spada F, Lim KHJ, Jacobs T, Barriuso J, Mansoor W, et al. Knowns and unknowns of bone metastases in patients with neuroendocrine neoplasms: A systematic review and meta-analysis. Cancer Treat Rev. 2021;94:102168.Journal
Cancer Treatment ReviewsDOI
10.1016/j.ctrv.2021.102168PubMed ID
33730627Additional Links
https://dx.doi.org/10.1016/j.ctrv.2021.102168Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.ctrv.2021.102168